Document:

Exhibit 10.9 

 

CONSULTING AGREEMENT

 

This Consulting Agreement
(the “Agreement”), effective as of this 11th day of February, 2016 (the “Effective Date”)
is entered into by and between Eurosa Inc. (herein referred to as the “Consultant”) and QPAGOS Corporation (herein
referred to as the “Company”).

 

RECITALS

 

WHEREAS, Company
desires to engage the services of Consultant to consult, assist with and advise the Company on certain strategic and tactical financial
matters;

 

NOW THEREFORE, in
consideration of the promises and the mutual covenants and agreements hereinafter set forth, the parties hereto covenant and agree
as follows:

 

1.Term.
Company hereby agrees to retain the Consultant to act in a consulting capacity to the Company, and the Consultant hereby agrees
to provide services to the Company commencing on the Effective Date and terminating 180 days thereafter unless terminated pursuant
to Section 8 of this Agreement.

 

2.Services.
During the term of this Agreement, Consultant’s services shall include, but will not necessarily be limited to, providing
the following services on behalf of and for the benefit of the Company:

 

2.1. Analyze Company’s corporate
awareness needs;

 

2.2 Consult, assist and advise
the Company on financial strategy and corporate awareness;

 

2.3
Consult and assist the Company in developing and implementing appropriate plans and material for

presenting the Company, its
business plan, strategy, and personnel to the financial community;

 

2.5 Otherwise
perform as the Company’s consultant in development of corporate awareness, financial

strategy and implementation; and

 

2.6
Assist with and advise the Company on relations with analysts and other investment professionals.

 

3.Allocation
of Time and Energies. Consultant hereby promises to perform and discharge faithfully the responsibilities which may be
assigned to the Consultant from time to time by the officers and duly authorized representatives of the Company under this Agreement.
Consultant shall diligently and thoroughly provide the consulting services required hereunder. Although no specific hours-per-day
requirement will be required, Consultant and the Company agree that Consultant will perform the duties set forth herein above in
a diligent and professional manner.

 

4.Remuneration.
As full and complete compensation for services described in this Agreement, the Company shall compensate Consultant as follows:

 

4.1 For undertaking
this engagement and for other good and valuable consideration, the Company agrees to cause to be delivered to Consultant, as a
single one-time payment, Nine Hundred Sixty Thousand (960,000) shares of the Company’s restricted common stock. Consultant
acknowledges that the shares issued to it involve a high degree of risk and further acknowledges that it and each of its equity
owners, is an accredited investor (as defined under Rule 501 of the Securities Act of 1933, as amended) and can bear the economic
risk of receiving the shares, which may include the total loss thereof, and each of its equity owners, is an accredited investor
(as defined under Rule 501 of the Securities Act of 1933, as amended). Consultant is not acquiring the shares with a view toward
distribution and is not an underwriter of, or dealer in, the common stock of the Company, nor is Consultant participating, pursuant
to a contractual agreement or otherwise, in the distribution of the Company’s common shares. The Consultant is not and has
not been subject to a “Bad Actor” Disqualification” under Section 506 of the Securities Act of 1933, as amended.

 

    

     

    

 

 

4.2The Company
shall be responsible for, and shall bear, all expenses directly and necessarily incurred in connection with Consultant’s
delivery of Services described in Paragraph 2. All expenses shall be pre-approved in writing by the Company.  

 

5.Secrets.
The Consultant agrees that any trade secrets or any other like information of value relating to the business of the Company or
any of its affiliates, or of any corporation or other legal entity in which the Company or any of its affiliates has an ownership
interest of more than twenty-five percent (25%), including but not limited to, information relating to inventions, disclosures,
processes, systems, methods, formulae, patents, patent applications, machinery, materials, research activities and plans, costs
of production, contract forms, prices volume of sales, promotional methods, list of names or classes of customers, which it has
heretofore acquired during its engagement by the Company or any of its affiliates or which it may hereafter acquire while delivering
Services hereunder as the result of any disclosures to it or any of its representatives or agents, or in any other way, shall be
regarded as held by the Consultant in a fiduciary capacity solely for the benefit of the Company, its successors or assigns, and
shall not at any time, either during the term of this Agreement or thereafter, be disclosed, divulged, furnished, or made accessible
by the Consultant to anyone, or be otherwise used by it or its representatives or agents except in the regular course of business
of the Company or its affiliates. Notwithstanding the foregoing, this covenant shall not be applicable to information that: (i)
is or becomes part of the public domain without breach of this Agreement; (ii) was known to Consultant on a non-confidential basis
prior to disclosure hereunder as evidenced by written documentation; (iii) is independently developed by the Consultant. This covenant
shall survive the termination of this Agreement.

 

6.Assignment.
This Agreement shall not be assigned by either party without the express written consent of the other party.

 

7.Notices.

 

7.1Any notices or other communications under
this Agreement shall be in writing and shall be deemed to have been given: when delivered personally against receipt therefore;
one day after being sent by Federal Express or similar overnight delivery; or three day after being mailed by registered or certified
mail, postage prepaid, to a party hereto at the address set forth below, or to such other address as such party shall give by notice
hereunder to the other party to this Agreement.

 

7.2Any notice to the
Company or to any assignee of the Company shall be addressed as follows:

 

7.3Any notice to Consultant
shall be addressed as follows:

 

QPAGOS Corporation

1900 Glades Road, Suite 265

Boca Raton, FL 33431

Attention: Gaston Pereira

 

    

     

    

 

 

Any notice to Consultant
shall be addressed as follows:

 

Eurosa Inc.

193 Walton Road, Suite
5

Seabrook, NH 03874

Attention: Sarmad Harake

7.4Either party may
change the address to which notice to it is to be addressed, by notice as provided herein.

 

 

8.Applicable
Law. This Agreement shall be interpreted and enforced in accordance with the laws of Delaware.

 

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

QPAGOS CORPORATION

 

 

By:    /s/ Gaston Pereira            

Name: Gaston Pereira

Title: Chief Executive Officer

 

EUROSA INC.

 

By:    /s/ Sarmad Harake           

Name: Sarmad Harake

Title: PresidentExhibit 10.74

 

ASSET PURCHASE
AGREEMENT

 

THIS
ASSET PURCHASE AGREEMENT is entered into as of December 11, 2015 (the “Effective
Date”) between PhotoMedex, Inc., a Delaware corporation with offices at 100 Lakeside Drive, Suite 100, Horsham,
PA 19044 (“PhotoMedex”), and The Lotus Global Group, Inc. dba GlobalMed Technologies Co., a California corporation
with offices at 15499 Arnold Drive, Suite A, Glen Ellen, CA 95442-9661 (“GlobalMed”).

 

WHEREAS,
PhotoMedex desires to assign, transfer and sell to GlobalMed all of PhotoMedex’ right, title and interest in and to all tangible
and intangible assets used in connection with PhotoMedex’ OmniluxTM product line (collectively, the “Omnilux Products”),
including all related intellectual property rights therein and thereto, and GlobalMed desires to purchase the Assets and accept
such transfer and assignment.

 

IT
IS AGREED, in consideration of GlobalMed’s payment of the Purchase Price (defined below) and each party’s covenants herein, as
follows:

 

Section 1.              Assignment
and Assumption.

 

1.1           Assignment
and Assumption. Effective on the Closing Date (defined below), PhotoMedex hereby sells, transfers, grants, conveys,
assigns and relinquishes exclusively to GlobalMed all of PhotoMedex’ right, title and interest in and to the assets set forth in
Exhibit A attached hereto (the “Assets”) in perpetuity.

 

Accordingly,
as of the Closing Date, GlobalMed, as owner of the Assets, acquires and succeeds to all of PhotoMedex’ right, title and standing
to: (i) receive all rights and benefits pertaining to the Assets, (ii) institute and prosecute all suits and proceedings and take
all actions that GlobalMed, in its sole and absolute discretion, deems necessary or advisable to collect, assert or enforce any
claim, right or title of any kind in and to the Assets, (iii) defend and compromise any and all such actions, suits or proceedings
relating to such assigned rights, title, interest and benefits, and (iv) do all such other acts and things in relation
thereto as GlobalMed, in its sole and absolute discretion, deems necessary or advisable.

 

Effective
on the Closing Date, GlobalMed hereby assumes only PhotoMedex’ warranty and maintenance obligations for PhotoMedex’ current installed
base of Omnilux Products (collectively, the “Existing Support Obligations”) and will (i) perform all Existing Support
Obligations and (ii) indemnify PhotoMedex against any third party claims to the extent arising out of GlobalMed’s failure to fulfill
the Existing Support Obligations. Schedule 1.1 attached hereto lists the entire installed base of Omnilux Products worldwide by
installation date and exact location.

 

1.1.1           Purchase
Price. GlobalMed will remit a total of US$ 220,000.00 for the Assets (the “Purchase Price”), payable
as follows: (i) promptly following the Effective Date, GlobalMed will remit US$ 110,000.00, 50% of the Purchase Price, to PhotoMedex
by wire transfer in accordance with instructions provided by PhotoMedex; and (ii) on the Closing Date, GlobalMed will remit the
balance of US$ 110,000.00 by wire transfer upon Closing. Until Closing and GlobalMed’s remittance of the full Purchase Price,
GlobalMed’s first payment will be fully refundable and will be promptly returned by PhotoMedex to GlobalMed on the termination
of this Agreement prior to Closing.

 

1.1.2           Allocation
of the Purchase Price. Each party acknowledges and agrees that the Purchase Price is allocated as follows: (i)
$200,000 to inventory, (ii) $10,000 to the covenant not to compete set forth in Section 5.2 below, and (iii) the balance to goodwill.
Following the Closing, each party will timely file Form 8594 with the Internal Revenue Service, setting forth this agreed asset
allocation.

 

    	 	 	 

     

    

 

1.1.3           Closing.
The closing of the sale of the Assets (the “Closing”) will take place promptly upon PhotoMedex’ completion
of all closing conditions set forth herein or such earlier date as agreed by the parties on GlobalMed’s waiver of any outstanding
closing condition (the “Closing Date”). However, GlobalMed, in its sole discretion, may terminate this Agreement prior
to Closing if PhotoMedex fails to meet any of its closing conditions and GlobalMed does not waive any such condition. PhotoMedex
has no right to terminate this Agreement other than on GlobalMed’s nonpayment of the Purchase Price under Section 1.1.1 above;
provided that PhotoMedex will give GlobalMed written notice of nonpayment and an opportunity to cure. All provisions that should
survive the Closing (i.e., indemnification, confidentiality) will so survive in accordance with their respective terms.

 

1.2           No
Assumption of Any Other Liabilities. Except for the Existing Support Obligations, GlobalMed will not assume any
of PhotoMedex’ other liabilities relating to the Assets or any liabilities of any other product lines or business of PhotoMedex
and/or any of its affiliates of any nature, whether known or unknown, absolute or contingent. Further to Section 3.2 below, PhotoMedex
will indemnify, defend and hold harmless GlobalMed from and against any and all such liabilities.

 

1.3           Limited
License Back to PhotoMedex. Effective on Closing but subject to the conditions set forth in the next paragraph,
GlobalMed hereby grants to PhotoMedex a limited, exclusive, worldwide, assignable, transferable and sub-licensable, and fully-paid
and royalty-free license to use, reproduce, distribute, modify and create derivative works from the Technical Information and
Proprietary Rights (each as defined on Exhibit A) and to make, have made,
offer for sale, sell (either directly or indirectly through distributors, resellers or other distribution channels), import or
otherwise dispose of any products created from or embodying any of such Technical Information and/or Proprietary Rights solely
and exclusively: (i) in PhotoMedex’s direct sale of skin care products to consumers and (ii) in the development and exploitation
of a helmet for military use to protect against brain and nervous system injuries under an existing contract with the US military.

 

PhotoMedex’s
license rights above are expressly subject to the following restrictions:

 

		(i)	PhotoMedex’s license under GlobalMed’s Proprietary
Rights expressly excludes any right to use or exploit any trademark, service mark, logo or tradename purchased by GlobalMed hereunder;
specifically, PhotoMedex may not use any Omnilux tradename, trademark, service mark or logo in any way in the exercise of such
rights nor will PhotoMedex attempt to register any logos, marks or tradenames similar to Omnilux;

 

		(ii)	PhotoMedex may only transfer, assign and/or sublicense
any of its license rights hereunder to a third party with GlobalMed’s prior written consent;

 

		(iii)	PhotoMedex’ license to use GlobalMed’s Technical Information
and Proprietary Rights will continue in perpetuity with respect to its development of military applications based on the helmet
described above; GlobalMed reserves the right to terminate PhotoMedex’ license to use GlobalMed’s Technical Information and Proprietary
Rights in the direct sale of skin care products to consumers if PhotoMedex fails to develop a viable market for such products
by the fifth anniversary of the Closing as reasonably determined by GlobalMed; and

 

    	 	2	 

     

    

 

		(iv)	if PhotoMedex develops any new technology from the
Technical Information or Proprietary Rights in the exercise of its license rights hereunder and the exploitation of such technology
is not expressly prohibited by the U.S. military or owned outright by the U.S. military, PhotoMedex will promptly notify GlobalMed
and, if such technology has any application to or for the Omnilux Products and/or GlobalMed’s current product line as reasonably
determined by GlobalMed, PhotoMedex will: (a) grant GlobalMed a nonexclusive, worldwide, assignable, transferable and sub-licensable,
perpetual and irrevocable, and fully-paid and royalty-free license to use, reproduce, distribute, modify and create derivative
works from the Technical Information and Proprietary Rights and to make, have made, offer for sale, sell (either directly or indirectly
through distributors, resellers or other distribution channels), import or otherwise dispose of any products created from or embodying
any such new technology, and (b) deliver all documentation, code and all other materials or information necessary or useful for
GlobalMed to exercise such license rights.

 

1.4           FDA/CE
Approval and/or Certification. For 180 days from the Closing Date or, if later, the date by which GlobalMed has all
necessary registrations, approvals and certifications from the U.S. Food and Drug Administration (“FDA”), from DEKRA,
attesting to compliance with application European Union legislation, and from ISO to manufacture, market and sell the Omnilux Products,
(i) PhotoMedex will designate GlobalMed as PhotoMedex’ sole distributor of record for purposes of FDA approvals and registrations,
CE markings and ISO certification for all Omnilux Products, (ii) PhotoMedex or its affiliate, PhotoTherapeutics Ltd., will remain
the manufacturer of record of all Omnilux Products for all regulatory requirements and import/export requirements, including on
all Omnilux Product labeling and packaging, and (ii) if a governmental entity recalls any Omnilux Product or subjects any Omnilux
Product to corrective action due to any pre-Closing events, acts or omissions, PhotoMedex will reimburse GlobalMed for all costs
incurred by GlobalMed in implementing that recall or corrective action and complying with the requirements thereof.

 

Section 2.              Representations
and Warranties.

 

		A.	PhotoMedex represents and warrants each of the following
to GlobalMed:

 

2.1           Corporate
Organization. PhotoMedex is a corporation duly organized, existing and in good standing under the laws of the State
of Delaware. PhotoMedex has the requisite power and authority to enter into and to satisfy all its obligations under this Agreement.
The execution and delivery by PhotoMedex of this Agreement, the performance by PhotoMedex of its obligations hereunder and the
consummation by PhotoMedex of the transactions contemplated hereby have been duly authorized by all necessary corporate action.
PhotoMedex is not required by law or its organizational documents to obtain shareholder approval of this Agreement or the sale
of Assets contemplated hereunder. This Agreement constitutes a valid and binding obligation, enforceable in accordance with its
terms, and when executed and delivered, will constitute a valid and binding obligation of PhotoMedex, enforceable against PhotoMedex
in accordance with its terms.

 

2.2           Title
to Assets: Sufficiency of Assets. PhotoMedex owns and has good and marketable title to, and has the unqualified
right to transfer, all the Assets. The Assets will be sold and conveyed to GlobalMed free and clear of all liens, creditor claims,
security interests, pledges, conditional sales agreements, leases, charges and encumbrances of any kind or nature. Except as set
forth on Schedule 2.2 attached hereto, PhotoMedex does not have any liabilities, obligations or commitments of any nature (whether
known or unknown, absolute, accrued, contingent, liquidated or otherwise) with respect to the Assets, including any liabilities
secured by any of the Assets. After giving effect to the sale, assignment and transfer of the Assets to GlobalMed pursuant to
this Agreement, GlobalMed will be the sole owner of the Assets, free of all obligations to pay any monies to any person. PhotoMedex’
sale of the Assets to GlobalMed will not constitute a bulk sale under Pennsylvania or New York law.

 

    	 	3	 

     

    

 

Further,
(i) the Assets constitute, in the aggregate, all of the property necessary for GlobalMed’s manufacture and sale of Omnilux Products
in the manner and to the extent currently conducted by PhotoMedex, (ii) other than the Assets, PhotoMedex does not own any other
tangible or intangible assets that constitute Omnilux Products or any part thereof or are necessary for the manufacture and commercial
distribution thereof, and (ii) the Assets currently in use and/or necessary for the manufacture of the Omnilux Products are in
good operating condition, normal wear and tear excepted. PhotoMedex knows of no communication, fact, event or action that has occurred
prior to the Effective Date or the Closing Date that would indicate that any customer, user, vendor, service provider or other
third party that is material to the exploitation of the Assets intends to terminate any of its agreements or its business relationship
with PhotoMedex or to significantly reduce the amount of business it does with PhotoMedex.

 

2.3           No
Default. Neither the execution of this Agreement nor the consummation of the transactions contemplated herein will
constitute or result in, whether at present or with the giving of notice and/or the passage of time, a material violation, breach
or default under: (1) any agreement, contract, covenant, lease, mortgage or other instrument to which PhotoMedex is a party or
by which it is, or the Assets are, bound; (2) any judgment, order, decree or other legal, judicial or governmental requirement
or mandate by which PhotoMedex is, or the Assets are, bound; or (3) PhotoMedex’ Certificate of Incorporation or Bylaws.

 

2.4           No
Litigation. There are no proceedings, claims, actions or legal proceedings pending or threatened against any of
the Omnilux Products or other Assets or against PhotoMedex that in any way relate to, involve or impact the Assets.

 

2.5           No
Consents. Except as set forth on Schedule 2.5, no consent, approval or authorization of, or declaration, filing
or registration with, any person or entity, including any government agency, is required for the execution, delivery and performance
by PhotoMedex of this Agreement and for the consummation by PhotoMedex of the transactions contemplated hereby.

 

2.6           Intellectual
Property Rights; No Infringement. For purposes of this Agreement and Exhibit
A. “Proprietary Rights” means all intellectual property and proprietary rights owned by PhotoMedex in or
pertaining to the Assets and/or utilized by PhotoMedex in connection with the Omnilux Products and other Assets; Exhibit
A contains a complete list of all PhotoMedex’ Proprietary Rights in existence as of the Effective Date. PhotoMedex
owns all right, title and interest in and to all the Proprietary Rights without any competing or superior third party claims;
to the best of PhotoMedex’ knowledge, no person or entity has infringed on, misappropriated or violated any of PhotoMedex’ Proprietary
Rights or is currently doing any of the foregoing.

 

PhotoMedex
has not infringed, misappropriated or otherwise violated or made unlawful use of any intellectual property right of any other person
with respect to the Assets. The operations of PhotoMedex with respect to the Assets, including the use, development, marketing,
distribution, provision, maintenance and support of any Omnilux Product, do not currently infringe, violate or make unlawful use
of any intellectual property right of any other person.

 

    	 	4	 

     

    

 

Each and
every person or entity that has created or developed any of PhotoMedex’ Proprietary Rights has executed a written assignment transferring
all intellectual property rights therein and thereto to PhotoMedex and copies of such assignments, which constitute Assets, will
be delivered by PhotoMedex to GlobalMed on or before Closing. None of the Assets and none of the Proprietary Rights therein and
thereto are licensed to PhotoMedex by any third party.

 

2.7           Information
Security. PhotoMedex has complied at all times and in all material respects with all of its privacy policies and
with all applicable legal requirements pertaining to privacy, user data and/or personal data, including personal health information,
in connection with the Assets.

 

2.8           No
Omission of Material Facts. None of the representations and warranties of PhotoMedex in this Section 2 contains
any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.

 

2.9           No
Bankruptcy. (i) PhotoMedex is not presently insolvent or involved in or a party to any insolvency or bankruptcy
proceeding, whether federal, state or foreign, (ii) PhotoMedex has not applied for the appointment of a trustee, receiver, liquidator
or other similar official and (iii) PhotoMedex does not anticipate instituting a voluntary bankruptcy or becoming subject to an
involuntary bankruptcy proceeding within the next 180 days.

 

2.10         Taxes.
All tax returns required to be filed by or on behalf of PhotoMedex with respect to the Assets or any of them have been
duly and timely filed, and all such tax returns are true, complete and correct. All taxes owed by or with respect to PhotoMedex
(whether or not shown on any tax return) or for which PhotoMedex could be liable with respect to the Assets, including all sales,
use and value added taxes, in whole or in part, have been paid. There are no tax liens upon any of the Assets, and, as of the
Effective Date, there is no basis upon which any governmental agency could impose a tax lien on any of the Assets. PhotoMedex
has withheld and paid all taxes required to have been withheld and paid in connection with amounts paid or owing to any employee,
contractor, creditor, stockholder or any other third party. PhotoMedex has properly charged, collected and paid all applicable
sales, use, value added and other similar taxes with respect to the Assets.

 

2.11         Legal
Compliance. PhotoMedex is and has been in compliance in all material respects with all laws, statutes and regulations
promulgated by any U.S. or foreign governmental body and all judgments applicable to the ownership or operation of the Assets.
PhotoMedex has not received any notice of any alleged violation (whether past or present and whether remedied or not) nor is PhotoMedex
aware of any basis for any claim of any such violation, of any such law, statute, rule, ordinance, regulation or judgment. There
is no law, statute or regulation promulgated by any governmental body or any judgment that materially and adversely affects or
is reasonably expected to materially and adversely affect the ability of GlobalMed to own and exploit the Assets.

 

		B.	GlobalMed makes the following representations and
warranties to PhotoMedex:

 

GlobalMed
is a corporation duly organized, existing and in good standing under the laws of the State of California. GlobalMed has the requisite
power and authority to enter into and to satisfy all its obligations under this Agreement. The execution and delivery by GlobalMed
of this Agreement, the performance by GlobalMed of its obligations hereunder and the consummation by GlobalMed of the transactions
contemplated hereby have been duly authorized by all necessary corporate action. This Agreement constitutes a valid and binding
obligation, enforceable in accordance with its terms, and when executed and delivered, will constitute a valid and binding obligation
of GlobalMed, enforceable against GlobalMed in accordance with its terms.

 

    	 	5	 

     

    

 

Neither the
execution of this Agreement nor the consummation of the transactions contemplated herein will constitute or result in, whether
at present or with the giving of notice and/or the passage of time, a material violation, breach or default under: (1) any agreement,
contract, covenant, lease, mortgage or other instrument to which GlobalMed is a party or by which it is bound; (2) any judgment,
order, decree or other legal, judicial or governmental requirement or mandate by which GlobalMed is bound; or (3) GlobalMed’s Certificate
of Incorporation or Bylaws.

 

Section 3.              Survival
of Representations; Indemnification.

 

3.1           Survival
of Warranties. Except in the case of PhotoMedex’ fraud, intentional misrepresentation and/or willful misconduct,
(i) all representations and warranties in this Agreement will expire one year from the Closing Date and (ii) claims for indemnification
brought under this Section 3 will be the sole and exclusive remedy of any Indemnitee (defined below) for monetary damages from
and after the Closing with respect to this Agreement. However, nothing contained in this Agreement will limit the rights of any
Indemnitee to seek or obtain injunctive relief or any other equitable remedy to which such Indemnitee is otherwise entitled.

 

3.2           Indemnification
by PhotoMedex. On GlobalMed’s demand, PhotoMedex will indemnify, defend and hold harmless GlobalMed, its present
and future shareholders, officers, directors, employees, agents and representatives, and their respective successors and assigns
(“Indemnitees”) from and against any and all claims, causes of
action, suits, liabilities, damages, taxes and expenses (including actual attorneys’ fees and costs reasonably incurred in defending
any such actions or to recover such losses) (“Losses”) that are
made against or sustained by any Indemnitee that arise, directly or indirectly, from: (i) any breach, default or violation by
PhotoMedex of any covenant, obligation, representation or warranty set forth in this Agreement or any related agreement or instrument
executed by PhotoMedex hereunder; (b) any material misrepresentation or omission of fact by PhotoMedex in this Agreement or any
related agreement or instrument executed by PhotoMedex hereunder, or (iii) all debts, expenses, obligations, claims or liabilities
arising with respect to the Assets prior to the Closing Date.

 

Section 4.              Covenants;
Closing Conditions

 

4.1           Confidentiality.
PhotoMedex acknowledges that GlobalMed’s success after the Closing Date depends upon the continued preservation of
the confidentiality of certain information possessed by PhotoMedex and that the preservation of the confidentiality of such information
is an essential premise of the bargain between the parties. Accordingly, PhotoMedex will not use any confidential or proprietary
information involving or relating to the Assets except for the benefit of GlobalMed.

 

Further,
subject to and in accordance with Exhibit B attached hereto and incorporated
herein, any and all information disclosed by either party to the other party will constitute the confidential information of the
disclosing party and each party will comply with the confidentiality obligations set forth in Exhibit
B.

 

4.2           Transfer
Taxes. PhotoMedex will be responsible for (and will indemnify and hold harmless GlobalMed and its respective directors,
officers, employees, affiliates, agents, successors and assigns against) one hundred percent (100%) of any sales, use, stamp,
documentary stamp, filing, recording, transfer or similar fees or taxes or governmental charges (including any interest and penalty
thereon) payable in connection with the transactions contemplated by this Agreement.

 

    	 	6	 

     

    

 

4.3           Further
Actions and Documents. On GlobalMed’s reasonable request at any time after the Effective Date, each of the parties
hereto will do, execute, acknowledge and deliver all such further acts, assurances, deeds, assignments, transfers, conveyances
and other instruments and papers as may be reasonably required or appropriate to carry out the transactions contemplated by this
Agreement in accordance with the terms herein. PhotoMedex will not take any action that is designed or intended to have the effect
of discouraging any subscriber, licensor, supplier, distributor or customer of PhotoMedex from maintaining the same relationship
with GlobalMed after the Effective Date as it maintained prior to the Effective Date.

 

If GlobalMed
is unable for any reason, after reasonable effort, to secure PhotoMedex’ execution of any document needed in connection with the
preceding paragraph, PhotoMedex hereby irrevocably designates and appoints GlobalMed and GlobalMed’s duly authorized officers as
PhotoMedex’ agents and attorneys-in-fact, which appointment is coupled with an interest, to act for and on PhotoMedex’ behalf solely
to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Section
4.3 with the same legal force and effect as if executed by PhotoMedex.

 

4.4           Closing
Conditions. GlobalMed’s obligation to consummate the transactions contemplated hereby is subject to the satisfaction
on or prior to the Closing Date of each of the following conditions, either of which may be waived, in writing and in whole or
in part, exclusively by GlobalMed in its sole discretion:

 

4.4.1           The
representations and warranties of PhotoMedex set forth in Section 2 above will be true and correct in all material respects at
and as of the Closing Date as if made on and as of the Closing Date and, as of the Closing Date, there will not have been any material
adverse change affecting the Omnilux Products or any of the Assets.

 

4.4.2           PhotoMedex’
Board of Directors will have consented in writing to this Agreement and the transactions contemplated hereunder, which consent
will be in the form reviewed and approved by GlobalMed.

 

4.4.3           PhotoMedex
will have renewed its registration of all the Omnilux Products with the FDA and provided GlobalMed with evidence of such annual
renewal issued or endorsed by the FDA.

 

4.5           GlobalMed
Board Approval. PhotoMedex’ obligation to consummate the transactions contemplated hereby is subject to GlobalMed’s
Board of Directors’ consent in writing, on or prior to the Closing Date, to this Agreement and the transactions contemplated hereunder,
which consent will be in the form reviewed and approved by GlobalMed under Section 4.4.2 above.

 

Section 5.              Miscellaneous.

 

5.1           Entire
Agreement. All previous agreements and negotiations made by the parties relating to the subject matter hereof are
hereby superseded and this Agreement, including its recital above and Exhibits A and
B below, embodies the entire understanding of the parties, there being no terms, conditions or obligations, oral or
written, express or implied, other than those contained herein. This Agreement may only be amended by a written document signed
by both parties.

 

    	 	7	 

     

    

 

The failure
of either party to enforce a provision of this Agreement will not be deemed a waiver of such provision or of the right of such
party thereafter to enforce such provision. If any provision of this Agreement is held unenforceable by a court of competent jurisdiction,
the remaining provisions will remain in full force and effect and, except as otherwise set forth in Section 5.2 below, the parties
will negotiate in good faith a substitute valid and enforceable provision that most nearly gives effect to the parties’ intent
in entering into this Agreement. Any notice required under this Agreement will be in writing and will be deemed received when delivered
by hand, registered or certified mail, courier or express delivery service or email with confirmation of receipt.

 

5.2           Non-Competition;
Non-Solicitation. Until the second anniversary of the Closing Date, throughout the world, PhotoMedex will not,
and PhotoMedex will cause its officers, directors, employees, majority shareholders, agents and representatives not to, (i) develop,
manufacture, license, commercially exploit and or support any product that competes with any Omnilux Product; (ii) directly or
indirectly as owner, shareholder or partner or otherwise, engage in any business that is similar to or competitive with the Omnilux
Products; (iii) disparage or defame GlobalMed or tortiously interfere with the contracts or other commercial relationships of
GlobalMed with respect to any of the Assets; (iv) recruit or solicit for employment or a contract position, directly or indirectly,
or offer to hire or hire any employee, contractor or agent of GlobalMed without GlobalMed’s prior written consent; and (v) solicit
or take away, directly or indirectly, or enter into an agreement or other commercial relationship with, any person, entity or
business that was a customer or prospective customer for the Omnilux Products without GlobalMed’s prior written consent or directly
or indirectly solicit or attempt to induce any customers or prospective customers for the Omnilux Products as of the Closing Date
to terminate their respective existing business relationships with Buyer after the Closing Date.

 

If a court
of competent jurisdiction determines that any of the restrictions set forth above is unreasonable or unenforceable, it is the intention
of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted
by the laws of that jurisdiction.

 

5.3           Governing
Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable
to contracts made and performed in such State without regard to conflicts of laws principles thereof. Any dispute or claim arising
out of or in connection with this Agreement will be finally settled by binding arbitration under the Rules of Arbitration of the
American Arbitration Association by one arbitrator appointed in accordance with said rules. If any legal action is necessary or
brought in any court or arbitration proceeding, to enforce or interpret the terms of this agreement, the prevailing party will
be entitled to reasonable attorney’s fees, costs, and necessary expenses, in addition to any other relief to which such party
may be entitled.

 

5.4           Expenses.
Each party to this Agreement will bear and pay all fees, costs and expenses (including legal fees) that have been incurred
or that are incurred by or on behalf of such party in connection with this Agreement.

 

5.5           Counterparts.
This Agreement may be executed in counterparts, each of which will constitute an original and both of which, when taken
together, will constitute one agreement. Counterpart signature pages to this Agreement may be delivered by facsimile or electronic
delivery (i.e., by email of a PDF signature page) and each such counterpart signature page will constitute an original for all
purposes.

 

    	 	8	 

     

    

 

5.6           Assignment.
This Agreement will be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns;
provided that neither party may assign this Agreement, in whole or in part, without the other party’s prior written consent. Nothing
in this Agreement will create or be deemed to create any third party beneficiary rights in any person or entity not a party to
this Agreement.

 

5.7           Press
Release. Within 30 days after the Closing Date, the parties will issue an agreed press release, announcing that
the parties have entered into the Agreement.

 

IN
WITNESS WHEREOF, each of the parties hereto has executed this Agreement, effective as of the Effective Date.

 

	PHOTOMEDEX,
    INC.	 	THE LOTUS GLOBAL GROUP, INC. DBA
	 	 	GLOBALMED TECHNOLOGIES CO.
	 	 	 	 	 
	By:	/s/
    Dennis McGrath	 	By:	/s/ Sanders
    Ergas
	 	Dennis McGrath, President
    and CFO	 	 	Sanders Ergas, President
    and CEO

 

    	 	9	 

     

    

 

EXHIBIT
A

ASSETS

 

1.          Any
and all information, documentation, materials, Technology and know-how required to manufacture the Omnilux Products and fulfill
the Existing Support Obligations (collectively, the “Technical Information”), including the materials identified below:

 

(i)
bills of materials (including components and other raw materials);

(ii)
product specifications, including material descriptions, functional descriptions, physical dimensions, engineering and other technical
drawings, brand names, parts numbers and contact information of all components, including modules, spare parts, labels and packing
materials;

(iii)
Omnilux Product documentation in electronic format, including all user and technical manuals; and

(iv) all
other technical and manufacturing information, including: (a) Software, schematics, designs, patterns, drawings or other
materials pertinent to the most current revision level of manufacturing of the Omnilux Products; (b) copies of all
inspection, manufacturing, test and quality control procedures and any other work processes; (c) jig, fixture and tooling
designs; (d) manufacturing history files; (e) support documentation; (f) any additional technical information deemed
necessary by Buyer to manufacture the Omnilux Products and/or fully exploit the Assets; (g) test reports; and (h) design
layouts, including circuit boards or circuitry therein.

 

“Technology”
means, collectively, all designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development,
recipes, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether patentable or
unpatentable and whether or not reduced to practice), apparatus, creations, improvements, works of authorship and other similar
materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other tangible embodiments of the foregoing,
in any form whether or not specifically listed herein.

 

“Software”
means any and all (i) computer programs, including any and all software implementations of algorithms, models and methodologies,
whether in source code or object code, (ii) databases and compilations, including any and all data and collections of data, whether
machine readable or otherwise, (iii) descriptions, flow-charts and other work product
used to design, plan, organize and develop any of the foregoing, screens, user interfaces, report formats, firmware, development
tools, templates, menus, buttons and icons, and (iv) all documentation, including user manuals and other training documentation,
related to any of the foregoing.

 

The
specific Technical Information, including equipment, that will be provided by PhotoMedex to GlobalMed is listed on Appendix I attached
to this Exhibit A and incorporated herein.

 

2.          All
of Seller’s proprietary and/or intellectual property rights in and to the Omnilux Products (including the right to make, use or
sell under patent law; to copy, adapt, distribute, display and perform under copyright law; and to use and disclose under trade
secret law), including all United States and foreign websites and domain names (including www.omnilux.co.uk.
trademarks (registered and unregistered), tradenames, service marks (including, in the case of trademarks, service marks and tradenames,
all goodwill appertaining thereto), logos, patents, patent applications, other discoveries and inventions whether or not patented
or patentable, trade secrets, technology, know-how, formulae, designs and drawings, computer software (source and object code),
programmer notes, software documentation, slogans, copyrights, processes, business methods, operating rights, other licenses and
permits, and other similar intangible property and rights relating to the Assets or embodied thereby, and any licenses with respect
to any of the foregoing (collectively, “Proprietary Rights”).

 

    	 	10	 

     

    

 

The specific
Proprietary Rights that will be transferred and assigned by PhotoMedex to GlobalMed are listed on Appendix II attached to this
Exhibit A and incorporated herein.

 

3.          Promptly
following the Closing Date and, in any event, by no later than January 10, 2015, at PhotoMedex’ expense, PhotoMedex will transfer
the ownership of its domain name(s) for the Omnilux Products to GlobalMed. Accordingly, PhotoMedex will modify its Whols Registration
Record(s) applicable to its domain name to change the Registrant, Technical Contact and Administrative Contact information to GlobalMed
and provide GlobalMed with the username(s) and password(s) required to access such Whols Registration Records. In addition, PhotoMedex
will transfer (i) all its federal and state trademark registrations specifically identified on Appendix
II to GlobalMed and (ii) all telephone numbers used in connection with the Omnilux Products and the Existing Support
Obligations. On the Closing Date, PhotoMedex will sign a patent assignment agreement, assigning all its Omnilux Products-related
patents to GlobalMed.

 

4.          Any
and all FDA, CE, DEKRA and/or ISO registrations, clearances, certifications, approvals and all other regulatory documents concerning
the Omnilux Products. Also, at PhotoMedex’ expense, all other federal, state and local licenses, permits, approvals and authorizations
previously granted to PhotoMedex for the Omnilux Products.

 

The specific
regulatory registrations, certifications and approvals that will be transferred and assigned by PhotoMedex to GlobalMed are listed
on Appendix III attached to this Exhibit A and incorporated herein.

 

5.          All
agreements, contracts and orders concerning the Omnilux Products, including PhotoMedex’ current manufacturing agreement and all
customer agreements, service agreements, supply contracts and other contracts made by PhotoMedex in the ordinary course and all
nondisclosure or confidentiality, noncompete, or non-solicitation agreements with employees, consultants and agents of PhotoMedex
or with third parties.

 

The specific
agreements, orders and other instruments that will be transferred and assigned by PhotoMedex to GlobalMed are listed on Appendix
IV attached to this Exhibit A and incorporated herein.

 

6.          Current
customer lists and registered user lists for the Omnilux Products, including contact information, all mailing lists, prospect databases,
supplier lists, vendor data, marketing information and procedures, sales and customer files, current product material, standard
forms of documents, manuals of operations or business procedures and other similar procedures and all other information relating
to the manufacture, marketing and sale of the Omnilux Products.

 

All of the
specific information described above that will be transferred and assigned by PhotoMedex to GlobalMed are listed on Appendix V
attached to this Exhibit A and incorporated herein.

 

7.          All
goodwill associated with the Omnilux tradename, the Omnilux Products and the Omnilux brand;

 

8.          Any
and all inventory of Omnilux Products located at any PhotoMedex facility or at the facility of its contract manufacturer(s); any
and all components and raw materials for the manufacture of Omnilux Products located at any PhotoMedex facility or at the facility
of its contract manufacturer(s); and any and all manufacturing equipment and related tangible assets for the manufacture and/or
servicing of the Omnilux Products, including jigs, fixtures and tooling, wherever located.

 

The specific
inventory and equipment that will be transferred and assigned by PhotoMedex to GlobalMed are listed on Appendix VI attached to
this Exhibit A and incorporated herein.

 

    	 	11	 

     

    

 

9.          All
causes of action, claims and other rights of every kind of Seller, including the right to sue third parties for past, present and
future infringement of any intellectual property or proprietary rights; all rights of PhotoMedex under nondisclosure or confidentiality,
non-compete, or non-solicitation agreements with employees, consultants and agents of PhotoMedex or with third parties.

 

10.         All
financial information, accounting and credit books and records, budgets and similar financial documents concerning the Omnilux
Products and PhotoMedex’ manufacture, sale and distribution thereof.

 

The specific
financial information that will be transferred and assigned by PhotoMedex to GlobalMed are listed on Appendix VII attached to this
Exhibit A and incorporated herein.

 

11.         All
other assets, properties and rights of every kind and nature owned by PhotoMedex or in which PhotoMedex has an interest, whether
known or unknown, fixed or unfixed, choate or inchoate, accrued, absolute, contingent or otherwise, whether or not specifically
referred to in this Agreement, in each case, to the extent relating to the manufacture, marketing, sale and distribution of the
Omnilux Products as currently conducted by PhotoMedex and to GlobalMed’s exploitation of the Assets.

 

All other assets,
properties and rights of every kind that will be transferred and assigned by PhotoMedex to GlobalMed and are not yet listed on
an Appendix attached hereto are listed on Appendix VIII attached to this Exhibit A
and incorporated herein.

 

    	 	12	 

     

    

 

EXHIBIT
B

MUTUAL
NONDISCLOSURE ADDENDUM

 

1.  Each
party (the “Disclosing Party,” as applicable) will provide the other party (the “Recipient,” as applicable)
with certain confidential and proprietary information, equipment or other materials (collectively, “Confidential Information”),
which Confidential Information may include, without limitation, marketing plans, research and development memoranda, prototypes,
technical information and other information containing trade secrets and know-how, intellectual property and financial information
and which Confidential Information may be disclosed in writing, orally or by inspection of tangible objects. In addition, the existence
and terms of the Agreement will be deemed to constitute Confidential Information. However, for the avoidance of any doubt, as of
the Effective Date, the Assets will constitute the Confidential Information of GlobalMed and will be protected by PhotoMedex for
the sole benefit of GlobalMed. If the Agreement terminates prior to Closing, the previous sentence will be null and void and of
no further force and effect; following Closing, Section 6 below will govern in perpetuity.

 

2.  Recipient
will maintain all Confidential Information disclosed hereunder by the Disclosing Party in confidence and will not use or exploit
such information or disclose such Information to any third party other than those of its employees, consultants, advisors, agents
or representatives with a need to know such Information; provided that each such person or entity must execute or have executed
an agreement or be subject to professional rules under which he, she or it is fully bound by the obligations of Recipient hereunder.
Recipient will not use or exploit the Confidential Information except as necessary to perform its obligations and exercise its
rights under the Agreement. Recipient will not reverse engineer or disassemble any software, equipment or other tangible objects
that embody or incorporate the Disclosing Party’s Confidential Information. Recipient will (i) mark any copies as Confidential
Information and retain the Disclosing Party’s proprietary notices, (ii) safeguard the Confidential Information with the same degree
of care that it uses to protect its own confidential information and in no event less than a reasonable standard of care and (iii)
immediately notify the Disclosing Party of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information.

 

3.  This
Agreement will not apply to any Confidential Information that (i) becomes generally available to the public through no fault or
breach of either party hereto or (ii) is required to be disclosed by Recipient as a matter of law or judicial or governmental mandate;
provided that Recipient will use all reasonable efforts to provide the Disclosing Party with an opportunity to appear and object
to such disclosure.

 

4.  The
Disclosing Party warrants that it has the right to disclose the Confidential Information to Recipient. Except as set forth in the
Agreement, including this Exhibit B, the Confidential Information disclosed
hereunder remains the property of the Disclosing Party and no license or other rights in or to such Information, including rights
under any trade secrets, copyrights or patents, is granted to Recipient hereby. THE CONFIDENTIAL INFORMATION DISCLOSED HEREUNDER
IS PROVIDED “AS IS” AND THE DISCLOSING PARTY MAKES NO REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS
THEREOF.

 

5.  Recipient
acknowledges that the Disclosing Party will suffer irreparable harm on any unauthorized disclosure of Confidential Information
by Recipient. Accordingly, on any breach hereof by Recipient, the Disclosing Party will be entitled to equitable relief, including
injunctive relief, in addition to any other remedies it may have at law or in equity.

 

6.  The
Recipient will hold the Disclosing Party’s Confidential Information in confidence in perpetuity. Specifically, PhotoMedex will
hold the Assets, including all of PhotoMedex’ Confidential Information, transferred, sold and assigned to GlobalMed under the Agreement
in confidence in perpetuity.

 

    	 	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]